<DOC>
	<DOC>NCT01357642</DOC>
	<brief_summary>This clinical study evaluates the 12-week efficacy and safety of Epinephrine HFA Inhalation Aerosol HFA the proposed HFA formulation of metered dose inhaler (MDI) of Epinephrine, in comparison to a Placebo-HFA control MDI and the currently marketed PrimateneÂ® Mist (epinephrine CFC inhaler), in adolescent and adult subjects with asthma.</brief_summary>
	<brief_title>Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients</brief_title>
	<detailed_description />
	<mesh_term>Asthma</mesh_term>
	<mesh_term>Epinephrine</mesh_term>
	<mesh_term>Racepinephrine</mesh_term>
	<mesh_term>Epinephryl borate</mesh_term>
	<criteria>Patients with documented asthma, requiring inhaled epinephrine or beta 2agonist treatment. No significant changes in asthma therapy and no asthmarelated hospitalization or emergency visits, within 4 weeks prior to Screening Can tolerate withholding treatment with inhaled bronchodilators and other allowed medications for the minimum washout period. Demonstrating a Screening Baseline FEV1 that is 50 90% of predicted normal value. Demonstrating at least a 12% Airway Reversibility. Demonstrating satisfactory techniques in the use of metereddose inhaler and a hand held peak expiratory flow meter. Female patients of childbearing potential must be nonpregnant and nonlactating at Screening and throughout the study, and must use an acceptable method of contraception during the study. A smoking history of 10pack years, or having smoked within 12 months of screening. Any current or past medical conditions that, per investigator discretion, might significantly affect responses to the study drugs, other than asthma. Concurrent clinically significant diseases. Known intolerance or hypersensitivity to any component of the study drugs. Recent infection of the respiratory tract, before screening. Use of prohibited medications. Having been on other investigational drug/device studies in the last 30 days prior to screening. Known or highly suspected substance abuse.</criteria>
	<gender>All</gender>
	<minimum_age>12 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>asthma</keyword>
	<keyword>bronchial asthma</keyword>
	<keyword>shortness of breath</keyword>
</DOC>